Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610296 · ClinicalTrials.gov registry record · Phase 3
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
A Phase 3 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
NCT02610296 is a Phase 3 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 594 participants.
The verdict
NCT02610296, a Phase 3 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors \>45 years after brain death (DBD).
Interventions
- OTHER Placebo
- DRUG QPI-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02610296
The ClinicalTrials.gov registry entry for NCT02610296 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 594 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02610296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02610296 about?
NCT02610296 is a clinical study titled "QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant". The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors \>45 years after brain death (DBD).
What is the current status of trial NCT02610296?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2016-03-01. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT02610296?
The interventions under investigation include: Placebo (OTHER), QPI-1002 (DRUG).
Who is sponsoring clinical trial NCT02610296?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.